Purpose Approximately 50%-74% of patients with metastatic human epidermal growth factor receptor 2 (HER2)–positive breast cancer do not respond to trastuzumab, with 75% of treated patients experiencing disease progression within a year. The combination of pyrotinib and capecitabine has showed efficacy in these patients. This study evaluates the efficacy and safety of pyrotinib combined with metronomic vinorelbine for trastuzumab-pretreated HER2-positive advanced breast cancer patients.
Materials and Methods In this phase 2 trial, patients aged 18-75 years with HER2-positive advanced breast cancer who had previously failed trastuzumab treatment were enrolled to receive pyrotinib 400 mg daily in combination with vinorelbine 40mg thrice weekly. The primary endpoint was progression-free survival (PFS), while secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety.
Results From October 21, 2019, to January 21, 2022, 36 patients were enrolled and received at least one dose of study treatment. At the cutoff date, 20 experienced disease progression or death. With a median follow-up duration of 35 months, the median PFS was 13.5 months (95% confidence interval [CI], 8.3 to 18.5). With all patients evaluated, an ORR of 38.9% (95% CI, 23.1 to 56.5) and a DCR of 83.3% (95% CI, 67.2 to 93.6) were achieved. The median OS was not reached. Grade 3 adverse events (AEs) were observed in 17 patients, with diarrhea being the most common (27.8%), followed by vomiting (8.3%) and stomachache (5.6%). There were no grade 4/5 AEs.
Conclusion Pyrotinib combined with metronomic vinorelbine showed promising efficacy and an acceptable safety profile in HER2-positive advanced breast cancer patients after trastuzumab failure.
Purpose The unique chromosomal rearrangements of endometrial stromal sarcoma (ESS) make it possible to distinguish high-grade ESS (HGESS) and low-grade ESS (LGESS) from the molecular perspective. Analysis of ESS at the genomic and transcriptomic levels can help us achieve accurate diagnosis of ESS and provide potential therapy options for ESS patients.
Materials and Methods A total of 36 ESS patients who conducted DNA- and/or RNA-based next-generation sequencing were retrospectively enrolled in this study. The molecular characteristics of ESS at genomic and transcriptomic levels, including mutational spectrum, fusion profiles, gene expression and pathway enrichment analysis and features about immune microenvironment were comprehensively explored.
Results TP53 and DNMT3A mutations were the most frequent mutations. The classical fusions frequently found in HGESS (ZC3H7B-BCOR and NUTM2B-YWHAE) and LGESS (JAZF1-SUZ12) were detected in our cohort. CCND1 was significantly up-regulated in HGESS, while the expression of GPER1 and PGR encoding estrogen receptor (ER) and progesterone receptor (PR) did not differ significantly between HGESS and LGESS. Actionable mutations enriched in homologous recombination repair, cell cycle, and phosphoinositide 3-kinase/AKT/mammalian target of rapamycin pathways were detected in 60% of HGESS patients. Genes with up-regulated expression in HGESS were significantly enriched in five immune-related pathways. Most HGESS patients (85.7%) had positive predictors of immunotherapy efficacy. Moreover, immune microenvironment analysis showed that HGESS had relatively high immune infiltration. The degree of immune infiltration in HGESS patients with ZC3H7B-BCOR fusion was relatively higher than that of those with NUTM2B-YWHAE fusion.
Conclusion This study investigated the molecular characteristics of ESS patients at the genomic and transcriptomic levels and revealed the potentially high sensitivity of targeted therapy and immunotherapy in a subset of HGESS with specific molecular features, providing a basis for guiding decision-making of treatment and the design of future clinical trials on precision therapy.
Citations
Citations to this article as recorded by
Integrated Transcriptomic Landscape and Deep Learning Based Survival Prediction in Uterine Sarcomas Yaolin Song, Guangqi Li, Zhenqi Zhang, Yinbo Liu, Huiqing Jia, Chao Zhang, Jigang Wang, Yanjiao Hu, Fengyun Hao, Xianglan Liu, Yunxia Xie, Ding Ma, Ganghua Li, Zaixian Tai, Xiaoming Xing Cancer Research and Treatment.2025; 57(1): 250. CrossRef
Genomic and T cell repertoire biomarkers associated with malignant mesothelioma survival Muwen Nie, Zhao Sun, Ningning Li, Liangrui Zhou, Shuchun Wang, Mingming Yuan, Rongrong Chen, Lin Zhao, Ji Li, Chunmei Bai Thoracic Cancer.2024; 15(19): 1502. CrossRef
Single-cell RNA-seq reveals FGF12 as a prognostic biomarker in low-grade endometrial stromal sarcoma Yu Miao, Meng Dong, Qiyin Zhou, Julia Thiel, Na Li, Ying Cai, Dan Yuan, Haitao Wang, Su-Han Jin, Hua Yang, Jinjing Wang, Benjamin Frey, Udo S. Gaipl, Hu Ma, Jian-Guo Zhou Frontiers in Immunology.2024;[Epub] CrossRef
High-Grade Endometrial Mesenchymal Sarcoma: Current Status and Future Trends Zhang Lushuang, Zhao Liubiqi Clinical Journal of Obstetrics and Gynecology.2023; 6(3): 132. CrossRef
Purpose
We sought to investigate the effectiveness and safety of dabrafenib in children with BRAFV600E-mutated Langerhans cell histiocytosis (LCH).
Materials and Methods
A retrospective analysis was performed on 20 children with BRAFV600E-mutated LCH who were treated with dabrafenib.
Results
The median age at which the patients started taking dabrafenib was 2.3 years old (range, 0.6 to 6.5 years). The ratio of boys to girls was 2.3:1. The median follow-up time was 30.8 months (range, 18.9 to 43.6 months). There were 14 patients (70%) in the risk organ (RO)+ group and six patients (30%) in the RO– group. All patients were initially treated with traditional chemotherapy and then shifted to targeted therapy due to poor control of LCH or intolerance to chemotherapy. The overall objective response rate and the overall disease control rate were 65% and 75%, respectively. During treatment, circulating levels of cell-free BRAFV600E (cfBRAFV600E) became negative in 60% of the patients within a median period of 3.0 months (range, 1.0 to 9.0 months). Grade 2 or 3 adverse effects occurred in five patients.
Conclusion
Some children with BRAFV600E-mutated LCH may benefit from monotherapy with dabrafenib, especially high-risk patients with concomitant hemophagocytic lymphohistiocytosis and intolerance to chemotherapy. The safety of dabrafenib is notable. A prospective study with a larger sample size is required to determine the optimal dosage and treatment duration.
Citations
Citations to this article as recorded by
Genetic Landscape and Its Prognostic Impact in Children With Langerhans Cell Histiocytosis Chan-Juan Wang, Lei Cui, Shuang-Shuang Li, Hong-Hao Ma, Dong Wang, Hong-Yun Lian, Yun-Ze Zhao, Li-Ping Zhang, Wei-Jing Li, Qing Zhang, Xiao-Xi Zhao, Ying Yang, Xiao-Tong Huang, Wei Liu, Yi-Zhuo Wang, Wan-Shui Wu, Tian-You Wang, Rui Zhang, Zhi-Gang Li Archives of Pathology & Laboratory Medicine.2025; 149(2): 175. CrossRef
Targeted therapy and immunotherapy for orbital and periorbital tumors: a major review Emmanuel Lee Boniao, Richard C. Allen, Gangadhara Sundar Orbit.2024; 43(5): 656. CrossRef
Treatment of children with refractory/relapse high risk langerhans cell histiocytosis with the combination of cytarabine, vindesine and prednisone Wenqian Wang, Jian Ge, Honghao Ma, Hongyun Lian, Lei Cui, Yunze Zhao, Zhigang Li, Tianyou Wang, Rui Zhang BMC Pediatrics.2024;[Epub] CrossRef
Vemurafenib combined with chemotherapy achieved sustained remission in pediatric LCH: a multi-center observational study Jiaying Lei, Wenxia Wang, Danna Lin, Chengguang Zhu, Wenguang Jia, Wenjun Weng, Xiaoshan Liu, Yuhan Ma, Zhixuan Wang, Lihua Yang, Xiangling He, Yunyan He, Yang LI Journal of Cancer Research and Clinical Oncology.2024;[Epub] CrossRef
Clinical features and treatment outcomes of liver involvement in paediatric Langerhans cell histiocytosis Xinshun Ge, Wenxin Ou, Ang Wei, Hongyun Lian, Honghao Ma, Lei Cui, Dong Wang, Liping Zhang, Xiaoman Wang, Lejian He, Rui Zhang, Tianyou Wang BMC Pediatrics.2024;[Epub] CrossRef
Refractory juvenile xanthogranuloma of the mastoid bone responsive to trametinib Isaac Hauk, Ignacio Gonzalez‐Gomes, Deepak Chellapandian, Jonathan Metts, Peter H. Shaw Pediatric Blood & Cancer.2024;[Epub] CrossRef
Advancements in the understanding and management of histiocytic neoplasms Kyung-Nam Koh, Su Hyun Yoon, Sung Han Kang, Hyery Kim, Ho Joon Im Blood Research.2024;[Epub] CrossRef
Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium Paul G. Kemps, F. J. Sherida H. Woei-A-Jin, Patrick Schöffski, Thomas Tousseyn, Isabelle Vanden Bempt, Friederike A. G. Meyer-Wentrup, Natasja Dors, Natasha K. A. van Eijkelenburg, Marijn A. Scheijde-Vermeulen, Ingrid M. Jazet, Maarten Limper, Margot Jak, Blood Neoplasia.2024; 1(3): 100023. CrossRef
The clinical impact of serum soluble CD25 levels in children with Langerhans cell histiocytosis Zi-Jing Zhao, Hong-Yun Lian, Wei-Jing Li, Qing Zhang, Hong-Hao Ma, Dong Wang, Yun-Ze Zhao, Ting Zhu, Hua-Lin Li, Xiao-Tong Huang, Tian-You Wang, Rui Zhang, Lei Cui, Zhi-Gang Li Jornal de Pediatria.2024;[Epub] CrossRef
Liver transplantation in a child with sclerosing cholangitis due to Langerhans cell histiocytosis: a case report Xue-Lian Wang, Chun-Xiao Fang, Min-Xia Chen, Hua-Mei Yang, Lan-Hui She, Yu Gong, Yi Xu, Wei-Qiang Xiao, Jin-Sheng Tian, Bin Ai, Li Huang, Xu-Fang Li Frontiers in Pediatrics.2024;[Epub] CrossRef
BRAF V600E gene mutation is present in primary intraosseous Rosai-Dorfman disease Lokman Cevik, Swati Satturwar, Dan Jones, Joel Mayerson, Steve Oghumu, O. Hans Iwenofu Human Pathology.2024; 154: 105702. CrossRef
Langerhans cell histiocytosis as a clonal disease of mononuclear phagocyte system Evgeniy F. Khynku, Maria K. Monaenkova, Olga B. Tamrazova, Alexey V. Taganov, Мarina А. Gureeva, Gayane E. Bagramova, Anton V. Molochkov Almanac of Clinical Medicine.2023; 50(7): 428. CrossRef
Lineage switching of the cellular distribution of BRAF
V600E in multisystem Langerhans cell histiocytosis Paul Milne, Simon Bomken, Olga Slater, Ashish Kumar, Adam Nelson, Somak Roy, Jessica Velazquez, Kshitij Mankad, James Nicholson, Dan Yeomanson, Richard Grundy, Ahmed Kamal, Anthony Penn, Jane Pears, Gerard Millen, Bruce Morland, James Hayden, Jason Lam, M Blood Advances.2023; 7(10): 2171. CrossRef
Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A Focus on MAPK Pathway Inhibitors Ashley V. Geerlinks, Oussama Abla Pediatric Drugs.2023; 25(4): 399. CrossRef
Dabrafenib, alone or in combination with trametinib, in BRAF V600–mutated pediatric Langerhans cell histiocytosis James A. Whitlock, Birgit Geoerger, Ira J. Dunkel, Michael Roughton, Jeea Choi, Lisa Osterloh, Mark Russo, Darren Hargrave Blood Advances.2023; 7(15): 3806. CrossRef
Therapiestrategien bei Kindern und Jugendlichen mit Langerhanszell
Histiozytosen Anke Elisabeth Barnbrock, Caroline Hutter, Konrad Bochennek, Milen Minkov, Thomas Lehrnbecher Klinische Pädiatrie.2023; 235(06): 342. CrossRef
Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasms Benjamin H. Durham, Oshrat Hershkovitz-Rokah, Omar Abdel-Wahab, Mariko Yabe, Young Rock Chung, Gilad Itchaki, Maayan Ben-Sasson, Vered A. Asher-Guz, David Groshar, Seyram A. Doe-Tetteh, Tina Alano, David B. Solit, Ofer Shpilberg, Eli L. Diamond, Roei D. M Blood Advances.2023; 7(23): 7319. CrossRef
Validation of Liquid Chromatography Coupled with Tandem Mass Spectrometry for the Determination of 12 Tyrosine Kinase Inhibitors (TKIs) and Their Application to Therapeutic Drug Monitoring in Adult and Pediatric Populations Marie Bellouard, Jean Donadieu, Pauline Thiebot, Etienne Giroux Leprieur, Philippe Saiag, Isabelle Etting, Pamela Dugues, Emuri Abe, Jean-Claude Alvarez, Islam-Amine Larabi Pharmaceutics.2023; 16(1): 5. CrossRef
Langerhans cell histiocytosis: promises and caveats of targeted therapies in high-risk and CNS disease Oussama Abla Hematology.2023; 2023(1): 386. CrossRef
Characteristics and Treatment Outcomes of Pediatric Langerhans Cell Histiocytosis with Thymic Involvement Ja-Feng Yao, Dong Wang, Hong-Hao Ma, Hong-Yun Lian, Li Zhang, Tian-You Wang, Zhi-Gang Li, Jin Jiang, Lei Cui, Rui Zhang The Journal of Pediatrics.2022; 244: 194. CrossRef
Clinical features and treatment outcomes of pediatric Langerhans cell histiocytosis with macrophage activation syndrome-hemophagocytic lymphohistiocytosis Dong Wang, Xi-Hua Chen, Ang Wei, Chun-Ju Zhou, Xue Zhang, Hong-Hao Ma, Hong-Yun Lian, Li Zhang, Qing Zhang, Xiao-Tong Huang, Chan-Juan Wang, Ying Yang, Wei Liu, Tian-You Wang, Zhi-Gang Li, Lei Cui, Rui Zhang Orphanet Journal of Rare Diseases.2022;[Epub] CrossRef
Current perspectives on the role of liver transplantation for Langerhans cell histiocytosis: A narrative review Jagadeesh Menon, Ashwin Rammohan, Mukul Vij, Naresh Shanmugam, Mohamed Rela World Journal of Gastroenterology.2022; 28(30): 4044. CrossRef
Research Progress of BRAF V600E Gene Mutation in Papillary Thyroid Carcinoma 延泽 刘 Advances in Clinical Medicine.2022; 12(09): 8499. CrossRef
Recent advances in the understanding of the molecular pathogenesis and targeted therapy options in Langerhans cell histiocytosis Jin Kyung Suh, Sunghan Kang, Hyery Kim, Ho Joon Im, Kyung-Nam Koh BLOOD RESEARCH.2021; 56(S1): S65. CrossRef
Improvement in Pituitary Imaging After Targeted Therapy in Three Children with BRAF-Mutated Langerhans Cell Histiocytosis with Pituitary Involvement
Ying Yang, Dong Wang, Na Li, Honghao Ma, Hongyun Lian, Lei Cui, Qing Zhang, Xiaoxi Zhao, Liping Zhang, Yunze Zhao, Chanjuan Wang, Li Zhang, Tianyou Wang, Zhigang Li, Rui Zhang OncoTargets and Therapy.2020; Volume 13: 12357. CrossRef
Purpose
Previous studies reported an association between an increased risk of tongue cancer and radiation treatment for nasopharyngeal carcinoma (NPC). This study compared the clinicopathologic characteristics and outcomes of tongue squamous cell carcinoma (TSCC) in patients with and without a history of radiotherapy for NPC.
Materials and Methods
From 1965 to 2009, a total of 73 patients were diagnosed with TSCC with a history of radiotherapy for NPC. The patients were matched in a 1:3 ratio with patients with sporadic TSCC according to age, sex, and year of the TSCC diagnosis. The primary endpoint was the overall survival.
Results
The median interval from NPC to TSCC was 82 months. The NPC survivors were more likely to be diagnosed with a more advanced T classification, less likely to have lymph node involvement, and more likely to have the tumor located in the dorsum of the tongue than sporadic TSCC. Regarding the histologic characteristics, the NPC survivors were more likely to have a weak lymphocytic host response, low tumor budding, and low risk of a worse pattern of invasion. The sporadic TSCC patients had a better overall survival (hazard ratio, 0.690; p=0.033) than the NPC survivors. In competing risks analysis, the cumulative incidence functions for the competing event (documented non-tongue cancer death) were significantly higher in the NPC survivors (Gray’s test, p=0.001).
Conclusion
TSCC patients with a history of radiotherapy for NPC appear to have particular clinicopathologic features, a poorer survival, and are more likely to die from non-tongue cancer causes than those with sporadic TSCC.
Citations
Citations to this article as recorded by
Radiotherapy upregulated immune checkpoints contribute to the development of second primary OSCC Li Wang, Siyu Wang, Jiayu Zhang, Jianmin Peng, Bin Cheng, Huan Li, Qinchao Hu Oral Diseases.2024; 30(4): 2188. CrossRef
Impact of histopathological parameters in prognosis of oral squamous cell carcinoma R. P. Ekanayaka, W. M. Tilakaratne Oral Diseases.2024;[Epub] CrossRef
Comparison of Clinical Outcomes, Pathologic Characteristics, and Immune-Related Features of Postradiation vs Sporadic Oral Cavity Squamous Cell Carcinoma James C. H. Chow, Wah Cheuk, William C. S. Cho, Chi-Fai Wong, Dennis W. Y. Au, Anthony H. P. Tam, Rachel C. W. Wong, Jeffrey C. H. Chan, Simon C. C. Law, Roger K. C. Ngan, Kam-Hung Wong, Ka-Man Cheung JAMA Network Open.2023; 6(7): e2323890. CrossRef
Clinical characterization of radiation-associated muscle-invasive bladder cancer Sybil T. Sha, Edward Christopher Dee, Matthew Mossanen, Brandon A. Mahal, Cierra Zaslowe-Dude, Trevor J. Royce, Michelle S. Hirsch, Guru Sonpavde, Mark A. Preston, Paul L. Nguyen, Kent W. Mouw, Vinayak Muralidhar Urology.2021; 154: 208. CrossRef
SPP1 and FN1 are significant gene biomarkers of tongue squamous cell carcinoma Xiao-Liang Xu, Hui Liu, Ying Zhang, Su-Xin Zhang, Zhong Chen, Yang Bao, Tian-Ke Li Oncology Letters.2021;[Epub] CrossRef
Secondary Squamous Cell Carcinoma of the Oral Cavity after Nasopharyngeal Carcinoma Liyuan Dai, Qigen Fang, Peng Li, Junfu Wu, Xu Zhang Cancer Research and Treatment.2020; 52(1): 109. CrossRef
Second primary cancer after intensity-modulated radiotherapy for nasopharyngeal carcinoma: A territory-wide study by HKNPCSG James C.H. Chow, Anthony H.P. Tam, Ka-Man Cheung, Victor H.F. Lee, Chi-Leung Chiang, Macy Tong, Edwin C.Y. Wong, Alice K.W. Cheung, Sunny P.C. Chan, Jessica W.Y. Lai, Roger K.C. Ngan, Wai-Tong Ng, Anne W.M. Lee, Kwok-Hung Au Oral Oncology.2020; 111: 105012. CrossRef
BET bromodomain inhibitor JQ1 promotes immunogenic cell death in tongue squamous cell carcinoma Miao Wang, Lu Zhao, Dongdong Tong, Linrui Yang, Hongjie Zhu, Qing Li, Fenghe Zhang International Immunopharmacology.2019; 76: 105921. CrossRef
Surgical treatment of early tongue squamous cell carcinoma and patient survival Lansheng Zhu, Yanling Wang, Rui Li, Aiqun Liu, Xiaoping Zhang, Chunran Zuo, Xiaoting Xu Oncology Letters.2019;[Epub] CrossRef
Keratin 6A gene silencing suppresses cell invasion and metastasis of nasopharyngeal carcinoma via the β‑catenin cascade Chuanjun Chen, Huiguo Shan Molecular Medicine Reports.2019;[Epub] CrossRef
Tumour budding in oral squamous cell carcinoma: a meta-analysis Alhadi Almangush, Matti Pirinen, Ilkka Heikkinen, Antti A Mäkitie, Tuula Salo, Ilmo Leivo British Journal of Cancer.2018; 118(4): 577. CrossRef
The poor outcome of second primary oral squamous cell carcinoma is attributed to Bmi1 upregulation Qinchao Hu, Tong Wu, Xiaobing Chen, Huan Li, Zhicheng Du, Yuantao Hao, Jianmin Peng, Shanshan Tai, Ming Song, Bin Cheng Cancer Medicine.2018; 7(4): 1056. CrossRef
Clinical analysis of second primary gingival squamous cell carcinoma after radiotherapy Xiaoyan Fu, Shuwei Chen, Weichao Chen, Zhongyuan Yang, Ming Song, Hao Li, Huayong Zhang, Fan Yao, Xuan Su, Tianrun Liu, An-Kui Yang Oral Oncology.2018; 84: 20. CrossRef